Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cytokinetics (DE:KK3A)
FRANKFURT:KK3A
Cytokinetics (KK3A) Stock Price & Analysis
1 Followers
KK3A Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€25.20 - €99.50
Previous Close€62
Volume0.00
Average Volume (3M)110.00
Market Cap
€6.57B
Enterprise Value€6.18B
Total Cash (Recent Filing)$614.82M
Total Debt (Recent Filing)$206.78M
Price to Earnings (P/E)N/A
Beta-0.26
Next Earnings
May 02, 2024EPS Estimate
-€1.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding103,004,710
10 Day Avg. Volume3
30 Day Avg. Volume110
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-18.11
Price to Sales (P/S)875.47
Price to Cash Flow (P/CF)-23.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue821.30
Enterprise Value/Gross Profit821.30
Enterprise Value/Ebitda-17.42
Forecast
1Y Price Target
€94.14Price Target Upside51.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
Cytokinetics News
Bulls Say, Bears Say
Bulls Say
Drug EfficacyAficamten shows potential as a best-in-class cardiac myosin inhibitor, with a differentiated pharmacology that may offer superior safety and equivalent efficacy based on SEQUOIA-HCM trial results.
Market ExpansionCytokinetics' aficamten could significantly expand the market for cardiac myosin inhibitors by offering benefits to patients with hypertrophic cardiomyopathy who remain symptomatic despite current therapies.
Regulatory ProgressRecent clinical trial data has been supportive for regulatory discussions, suggesting a strong profile for aficamten and a differentiated approach to patient treatment.
Bears Say
Drug Efficacy And SafetyConcerns arise from aficamten's unclear competitive edge in efficacy and safety over similar molecules.
Financial HealthThe financial guidance indicates significant operational expenses, but the current cash balance and additional funding sources are expected to provide a cash runway for approximately two years.
Regulatory ChallengesQuestions regarding a lesser REMS program may not be answered until FDA approval.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.13% Other Institutional Investors
99.87% Public Companies and
Individual Investors
KK3A FAQ
What was Cytokinetics’s price range in the past 12 months?
Cytokinetics lowest stock price was €25.20 and its highest was €99.50 in the past 12 months.
What is Cytokinetics’s market cap?
Currently, no data Available
When is Cytokinetics’s upcoming earnings report date?
Cytokinetics’s upcoming earnings report date is May 02, 2024 which is in 7 days.
How were Cytokinetics’s earnings last quarter?
Cytokinetics released its earnings results on Feb 27, 2024. The company reported -€1.3 earnings per share for the quarter, missing the consensus estimate of -€0.902 by -€0.397.
Is Cytokinetics overvalued?
According to Wall Street analysts Cytokinetics’s price is currently Undervalued.
Does Cytokinetics pay dividends?
Cytokinetics does not currently pay dividends.
What is Cytokinetics’s EPS estimate?
Cytokinetics’s EPS estimate is -€1.08.
How many shares outstanding does Cytokinetics have?
Currently, no data Available
What happened to Cytokinetics’s price movement after its last earnings report?
Cytokinetics reported an EPS of -€1.3 in its last earnings report, missing expectations of -€0.902. Following the earnings report the stock price went down -8.784%.
Which hedge fund is a major shareholder of Cytokinetics?
Among the largest hedge funds holding Cytokinetics’s share is Farallon Capital Management, L.L.C.. It holds Cytokinetics’s shares valued at 91M.
---
Cytokinetics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€94.14 (51.85% Upside)
€94.14 (51.85% Upside)
Blogger Sentiment
Bullish
DE:KK3A Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $2.4M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
86.56%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-18.77%
Trailing 12-Months
Company Description
Cytokinetics
Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.
---
KK3A Earnings Call
Q4 2024
0:00 / 0:00
---
KK3A Stock 12 Months Forecast
Average Price Target
€94.14
▲(51.85% Upside)
Technical Analysis
Cytokinetics
―
Kura Oncology
―
Xenon
―
Ultragenyx Pharmaceutical
―
Voyager Therapeutics
―
Best Analysts Covering KK3A
1 Year
1 Year Success Rate
19/26 ratings generated profit
1 Year Average Return
+39.22%
reiterated a buy rating 4 months ago
Copying Charles Duncan's trades and holding each position for 1 Year would result in 73.08% of your transactions generating a profit, with an average return of +39.22% per trade.
---